MoonLake Immunotherapeutics - Class A opened lower at $13.40, compared with its previous close of $13.51. In the last trading session, the stock traded between $12.87 and $13.47. It showed a downward intraday trend.
An investment of $100 made 5 years ago in MoonLake Immunotherapeutics - Class A is now worth
$ 105.10
Giving a profit of
$ 5.10 (5.10%)
Note: Past profits do not guarantee future returns.
Rating from 8 Analysts
Today's Change
$-0.64 (-4.70%)
Day High
$13.47
Day Low
$12.87
Day Open
$13.40
Prev Close
$13.51
Volume
13,06,368
1W Return
11.31%
1M Return
20.53%
3M Return
-22.53%
6M Return
-31.66%
1Y Return
9.57%
Market Cap ($ Mn)
1,096
PE Ratio
-
PB Ratio
2.93
PEG Ratio
-
ROE
-63.93%
ROCE
-52.46%
EPS (TTM)
$-0.93
1 Week
11.31%
1 Month
20.53%
3 Months
-22.53%
6 Months
-31.66%
9 Months
-18.46%
MoonLake Q3FY26 Results: Net loss widens to $79.5 million on higher R&D
Submitted BLA to FDA for sonelokimab in hidradenitis suppurativa, with PDUFA date expected mid-December 2026. Net loss widened to $79.5 million in Q3 2026 from $61.8 million in Q2, driven by higher R&D expenses. R&D expenses rose 37% QoQ to $68.9 million due to accrued milestone license fees for BLA submission. Held $498.5 million in cash and equivalents as of September 30, 2026, with a projected runway to mid-2028. Phase 3 IZAR-1 trial met all Week 16 endpoints for psoriatic arthritis, with 42.1% achieving ACR50 response.
8 days agoMoonLake Immunotherapeutics shares rise 18% on competitor efficacy gap
MoonLake Immunotherapeutics shares rose 18.59% to $12.63 on Thursday. AbbVie's lutikizumab showed 31.4% HiSCR75 response vs 23.4% placebo. Treatment difference of 8.0% trails UCB SA's 15%-20% benchmark range. Sonelokimab achieved 67.2% HiSCR75 response at Week 52 in Phase 3 trials. Commercial launch anticipated in second half of 2027 pending FDA review.
21 days agoMoonLake Immunotherapeutics files FDA BLA for sonelokimab to treat hidradenitis suppurativa
MoonLake Immunotherapeutics filed a Biologics License Application with the US FDA. The application seeks approval for sonelokimab to treat hidradenitis suppurativa. The filing was submitted as an 8-K form to the SEC.
1mo agoMoonLake’s sonelokimab meets PsA endpoints; stock falls 6%
MoonLake Immunotherapeutics reported positive Phase 3 IZAR-1 trial results for sonelokimab in psoriatic arthritis, achieving all primary and secondary endpoints at Week 16. Key metrics included a 42.1% ACR50 response rate and 61% PASI90 response in patients with skin involvement. Despite the strong clinical data, the company's stock fell 6.3% to $17.11. The company holds $537.0 million in cash with a runway to mid-2028.
3mo agoMoonLake Q2 Results: EPS of $(0.84) beats estimates
MoonLake Holdings delivered Q2 EPS of $(0.84), beating the $(0.93) estimate by 9.68%. This marks a 3.45% YoY improvement over prior year losses of $(0.87).
3mo agoHC Wainwright reiterates Buy rating on MoonLake
HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a Buy rating for MoonLake (NASDAQ: MLTX) with a maintained price target of $45.
3mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $547.03 | -0.16% | $1,38,692.89M | 31.55 | |
| $61.05 | +0.38% | $1,31,510.31M | 14.39 | |
| $248.69 | -0.85% | $1,00,625.20M | - | |
| $959.41 | +4.73% | $97,505.80M | 19.64 | |
| $977.58 | +0.62% | $61,476.10M | 38.99 | |
| $419.98 | -0.95% | $46,108.31M | 65.60 | |
| $180.70 | -6.40% | $39,083.96M | - | |
| $53.87 | -0.37% | $33,618.11M | 26.24 | |
| $70.01 | +0.81% | $31,173.07M | 32.37 | |
| $41.85 | +1.60% | $30,322.88M | - | |
| $120.75 | +1.05% | $26,490.14M | - | |
| $122.27 | +1.64% | $24,922.54M | 15.85 |
An investment of $100 made 5 years ago in MoonLake Immunotherapeutics - Class A is now worth
$ 105.10
Giving a profit of
$ 5.10 (5.10%)
Note: Past profits do not guarantee future returns.
